Holen Sie sich die Stockscreener-App
126.18
0.68%
-0.86
Handel nachbörslich:
128.01
1.83
+1.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$127.04
Offen:
$127.1
24-Stunden-Volumen:
4.32M
Relative Volume:
0.71
Marktkapitalisierung:
$219.41B
Einnahmen:
$43.84B
Nettoeinkommen (Verlust:
$13.90B
KGV:
15.83
EPS:
7.9725
Netto-Cashflow:
$6.92B
1W Leistung:
+0.71%
1M Leistung:
+3.35%
6M Leistung:
-5.38%
1J Leistung:
+10.44%
1-Tages-Spanne:
$126.06
$128.10
1-Wochen-Bereich:
$122.50
$129.46
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.18 | 220.91B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.38 | 146.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.21 | 140.64B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.69 | 127.91B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.58 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Exact Sciences: Abbott Acquisition A Positive Sign For Oncology Diagnostics (NASDAQ:EXAS) - Seeking Alpha
Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns - simplywall.st
17-year Abbott employee sues, alleges firing over approved FMLA use - HRD America
Abbott: Not Cheap, But Built To Compound In Uncertain Markets (NYSE:ABT) - Seeking Alpha
Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy - The Globe and Mail
Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize
Abbott’s New Libre Assist AI Tool Might Change The Case For Investing In Abbott Laboratories (ABT) - simplywall.st
Abbott Laboratories (NYSE:ABT) Given New $144.00 Price Target at Evercore ISI - MarketBeat
Should Abbott’s AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors? - Yahoo Finance
Hematology Market Booming with Rapid Growth Through 2033 | - openPR.com
Abbott Laboratories $ABT Shares Sold by Commonwealth Equity Services LLC - MarketBeat
Abbott (ABT) Rises Higher Than Market: Key Facts - Yahoo Finance
Abbott unveils new FreeStyle Libre app feature for mealtime decisions - MassDevice
How to listen as Abbott breaks down its latest quarterly results Jan. 22 - Stock Titan
In wake of Minnesota fraud, Abbott directs investigation into childcare programs - TPI Media Group
Abbott Laboratories Stock Gains Momentum from AI and Analyst Confidence - AD HOC NEWS
Abbott Laboratories (NYSE:ABT) Price Target Raised to $169.00 - MarketBeat
Railway Pension Investments Ltd Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Healthcare Weight In S&P 500 Chart - Kalkine Media
Synergy Asset Management LLC Sells 40,094 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Asset Management One Co. Ltd. - MarketBeat
2 Healthcare Stocks to Buy in a Bear Market - The Globe and Mail
JARISLOWSKY FRASER Ltd Has $289.05 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Has A Rock Solid Balance Sheet - 富途牛牛
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT) - simplywall.st
Tectonic Advisors LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
The Truth About Abbott Laboratories: Is This ‘Boring’ Stock Actually a Secret Power Play? - AD HOC NEWS
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Allspring Global Investments Holdings LLC Acquires 69,578 Shares of Abbott Laboratories $ABT - MarketBeat
Bank Pictet & Cie Europe AG Has $9.82 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature - FinancialContent
Ninety One SA PTY Ltd Takes $1.49 Million Position in Abbott Laboratories $ABT - MarketBeat
Mather Group LLC. Raises Position in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Acquires 20,035 Shares of Abbott Laboratories $ABT - MarketBeat
With EPS Growth And More, Abbott Laboratories (NYSE:ABT) Makes An Interesting Case - Yahoo Finance
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings? - TradingView — Track All Markets
The Truth About Abbott Laboratories: Viral Hype Or Boring Boomer Stock You’re Sleeping On? - AD HOC NEWS
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
Shum Financial Group Inc. Acquires Shares of 8,127 Abbott Laboratories $ABT - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 245,400 Shares of Abbott Laboratories $ABT - MarketBeat
Brendel Financial Advisors LLC Sells 23,978 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus - ts2.tech
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment - Finviz
Traders Buy Large Volume of Call Options on Abbott Laboratories (NYSE:ABT) - MarketBeat
Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger - The Globe and Mail
Oak Harvest Investment Services Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Diversified Trust Co Boosts Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Walks a Tightrope Between Defensive Haven and Growth Re?Rating - AD HOC NEWS
Abbott Laboratories (NYSE:ABT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
U.S. Embolic Protection Devices Market and Competition - GlobeNewswire
U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More - Yahoo Finance
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
2.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):